"Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5." by Mehdi Hamadani

Article

Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

Journal of Clinical Oncology (2021)

Mehdi Hamadani, Medical College of Wisconsin
Yuliya Linhares, Baptist Health
Mitul Gandhi, Medical Oncology, Virginia Cancer Specialists, Gainesville, VA;
Michael Chung, Hematology/Oncology, The Oncology Institute of Hope and Innovation, Downey, CA;
Helena Adamis, Clinical Development, ADC Therapeutics, Epalinges, Switzerland;
David Ungar, Clinical Development, ADC Therapeutics America, Inc, Murray Hill, NJ;
Carmelo Carlo-Stella, Humanitas University

Link

Disciplines

Publication Date

May 20, 2021

DOI

10.1200/JCO.2021.39.15_SUPPL.TPS7574

Citation Information

Mehdi Hamadani, Yuliya Linhares, Mitul Gandhi, Michael Chung, et al.. "Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5." Journal of Clinical Oncology Vol. 39 (2021)
Available at: http://works.bepress.com/yuliya-linhares/37/